好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Menopause and Late-life Structural Brain Aging
Aging, Dementia, and Behavioral Neurology
P9 - Poster Session 9 (5:00 PM-6:00 PM)
13-012

Additional selection bias may arise because women cognitive decline before age 65, statistically more likely to be those with early surgical menopause, were excluded.

Early and surgical menopause are linked to increased AD risk and faster cognitive decline, but mechanisms remain unclear. Shorter reproductive lifespan (RLS: menarche to menopause) is at midlife associated with gray matter loss, but its association with late-life brain volume trajectories is uncertain.

Female participants in the Religious Orders Study/Memory and Aging Project cohorts were analyzed. Associations between reproductive factors, brain volumes (total, gray and white matter volume), and global cognition were evaluated using mixed-effects models adjusted for age, education, smoking, and cohort. Global AD neuropathology was examined using linear models.

In the entire cohort (n=2,398; mean age=78.1±7.8; global cognition=0.12±0.58 at baseline), older menopause age (Est=0.0008, P=0.03), and MHT exposure (Est=0.28, P=0.00008), were both associated with slower cognitive decline. Later surgical menopause was associated with lower AD neuropathology (Est=–0.005, P=0.05) and AD risk (OR=0.97, 95%CI 0.94–0.99, P=0.03). Unexpectedly, in the subset with longitudinal MRIs (n=430), older menopause age was associated with faster total brain volume loss (Est=–0.005, P=0.02). Compared to the larger cohort, at study entry this group were younger (76.8±7.5) with higher cognition (0.37±0.46).

Extended estrogen exposure–via later menopause or timely MHT–appears to confer cognitive and pathological resilience to AD. The paradoxical association observed here between later menopause and faster brain atrophy, highlights possible cohort biases. Indeed, the younger age and cognitive preservation in the MRI subsample at study entry potentially reflected survivor effects; those with early decline (perhaps likeliest to have early surgical menopause) were excluded, introducing selection bias. Altogether, these findings point to the importance of careful interpretation and replication when analyzing the contribution of mid-life contributors, such as reproductive lifespan, to later-life cognitive decline.

Authors/Disclosures
Maria Pia Campagna, PhD
PRESENTER
Dr. Campagna has nothing to disclose.
David A. Bennett, MD (Rush University Medical Center) Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annovis. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for New Amsterdam. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie.
Lisa L. Barnes, PhD (Rush University Medical Center) Lisa L. Barnes has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer's & Dementia. The institution of Lisa L. Barnes has received research support from NIH. Lisa L. Barnes has received personal compensation in the range of $500-$4,999 for serving as a Council member with NACMHD.
Julie A. Schneider, MD, MS (Rush Alzheimer'S Disease Center) Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Schneider has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for alnylam. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for apellis. Dr. Schneider has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for National Hockey League. The institution of Dr. Schneider has received research support from NIH. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a scientific advisor with Fondation Alzheimer, France.
Riley Bove, MD, FAAN (University of California, San Francisco) Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD-Serono. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadenza. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Eli Lilly. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Roche Genentech.